Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Ying-Ming Jou · SciRah

Researcher profile · Semantic Scholar

Ying-Ming Jou

Share profile

Ying-Ming Jou — researcher profile on SciRah

h-index: 15
Works: 33
Citations: 1,780

Most-cited papers

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
M. Dimopoulos, D. Dytfeld, S. Grosicki, P. Moreau +13 more
2018New England Journal of Medicine458 citations Open access
Semantic Scholar
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM.
A. Jakubowiak, M. Offidani, B. Pégourié, J. de la Rubia +14 more
2016Blood229 citations Open access
Semantic Scholar
Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.
M. Mita, A. Joy, A. Mita, K. Sankhala +8 more
2014Clinical Breast Cancer141 citations
Semantic Scholar
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
J. Nemunaitis, Karen A. Small, P. Kirschmeier, Da Zhang +5 more
2013Journal of Translational Medicine135 citations Open access
Semantic Scholar
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
M. Dimopoulos, S. Lonial, D. White, P. Moreau +24 more
2020Blood Cancer Journal134 citations Open access
Semantic Scholar
Anti-tumour activity in RAS-driven tumours by blocking AKT and MEK
A. Tolcher, K. Khan, M. Ong, U. Banerji +21 more
2014Clinical Cancer Research128 citations Open access
Semantic Scholar
Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
J. Stephenson, J. Nemunaitis, A. Joy, Julie C. Martin +9 more
2014Lung Cancer100 citations
Semantic Scholar
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
M. Dimopoulos, D. Dytfeld, S. Grosicki, P. Moreau +12 more
2022Journal of Clinical Oncology94 citations Open access
Semantic Scholar
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
I. Gojo, M. Sadowska, Alison R. Walker, E. Feldman +10 more
2013Cancer Chemotherapy and Pharmacology85 citations Open access
Semantic Scholar
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies
M. Mita, A. Mita, Jennifer L Moseley, J. Poon +13 more
2017British Journal of Cancer50 citations Open access
Semantic Scholar
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
M. Dimopoulos, P. Richardson, N. Bahlis, S. Grosicki +22 more
2022The Lancet Haematology42 citations Open access
Semantic Scholar
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study
S. Jagannath, J. Laubach, E. Wong, K. Stockerl-Goldstein +8 more
2018British Journal of Haematology38 citations Open access
Semantic Scholar
Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus
L. Ji, P. Han, Xiaoyue Wang, Jing-Dong Liu +7 more
2016Journal of Diabetes Investigation33 citations Open access
Semantic Scholar
Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up
A. Palumbo, M. Offidani, B. Pégourié, J. de la Rubia +11 more
201519 citations
Semantic Scholar
A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
A. Jakubowiak, M. Offidani, B. Pégourié, J. de la Rubia +13 more
201518 citations
Semantic Scholar
Response-Adapted Therapy with Nivolumab and Brentuximab Vedotin (BV), Followed By BV and Bendamustine for Suboptimal Response, in Children, Adolescents, and Young Adults with Standard-Risk Relapsed/Refractory Classical Hodgkin Lymphoma
P. Harker-Murray, T. Leblanc, M. Mascarin, C. Mauz-Körholz +14 more
2018Blood15 citations
Semantic Scholar
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.
Hans C. Lee, K. Ramasamy, K. Weisel, R. Abonour +16 more
2022Clinical Lymphoma, Myeloma & Leukemia10 citations Open access
Semantic Scholar
PS1370 ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY
M. Dimopoulos, D. Dytfeld, S. Grosicki, P. Moreau +13 more
2019HemaSphere9 citations Open access
Semantic Scholar
Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC).
Irene Braña, K. Moore, R. Shapira-Frommer, S. Welch +5 more
20137 citations
Semantic Scholar
Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial
M. Dimopoulos, K. Weisel, S. Lonial, D. White +17 more
2019Clinical Lymphoma, Myeloma & Leukemia6 citations
Semantic Scholar
Effects of elotuzumab on QT interval and cardiac safety in patients with multiple myeloma
C. Passey, R. Darbenzio, Ying-Ming Jou, M. Lynch +1 more
2016Cancer Chemotherapy and Pharmacology6 citations
Semantic Scholar
P-193: Elotuzumab plus pomalidomide/dexamethasone for relapsed/refractory multiple myeloma: final overall survival from the phase 2 ELOQUENT-3 trial
M. Dimopoulos, D. Dytfeld, S. Grosicki, P. Moreau +12 more
2021Clinical Lymphoma, Myeloma & Leukemia5 citations
Semantic Scholar
Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study
M. Dimopoulos, D. Dytfeld, S. Grosicki, P. Moreau +13 more
2019Clinical Lymphoma, Myeloma & Leukemia5 citations
Semantic Scholar
Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the ConnectⓇ MM Registry.
H. Terebelo, J. Omel, L. I. Wagner, J. Hardin +13 more
2024Clinical Lymphoma, Myeloma & Leukemia4 citations Open access
Semantic Scholar
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry
S. Ailawadhi, Hans C. Lee, J. Omel, K. Toomey +12 more
2024Blood Cancer Journal3 citations Open access
Semantic Scholar
Nivolumab and daratumumab combination regimens for the treatment of relapsed and refractory multiple myeloma: results of a randomized phase I/II clinical trial
Al-Ola A. Abdallah, A. Lesokhin, Tomasz Wróbel, Krzysztof Jamroziak +19 more
2023Frontiers in Hematology3 citations Open access
Semantic Scholar
Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study
M. Hori, N. Takezako, Kazutaka Sunami, S. Ito +6 more
2018Blood3 citations
Semantic Scholar
Abstract 4718: A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor dinaciclib (SCH 727965) in patients with advanced breast cancer
M. Mita, A. Joy, A. Mita, K. Sankhala +9 more
20111 citations
Semantic Scholar
Abstract 2242: A randomized phase 2 study of the cyclin-dependent kinase (CDK) inhibitor Dinaciclib (SCH 727965) in patients with non-small cell lung cancer (NSCLC)
S. Warren, J. Nemunaitis, J. Stephenson, B. Samson +8 more
20111 citations
Semantic Scholar
Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry
Joshua Richter, S. Ailawadhi, Hans C. Lee, J. Hardin +14 more
2022Blood0 citations Open access
Semantic Scholar
P-229: Real-world outcomes of sequencing elotuzumab (elo)-based regimens following daratumumab (dara) in patients with relapsed/refractory multiple myeloma: results from the Connect® MM Registry
S. Ailawadhi, B. Durie, M. Narang, J. Omel +14 more
2022Clinical Lymphoma, Myeloma & Leukemia0 citations
Semantic Scholar
Abstract B181: TP53 mutation screening in patients with recurrent platinum-sensitive ovarian cancer.
Irene Braña, K. Moore, S. Welch, R. Shapira-Frommer +13 more
20130 citations
Semantic Scholar
Nonparametric Estimation of Heterogeneous Recombination Rates Across the Mouse Genome
Ying-Ming Jou, G. Churchill
19990 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Dimopoulos×9
Invite
M. Dimopoulos — researcher profile on SciRah
S. Grosicki×8
Invite
S. Grosicki — researcher profile on SciRah
P. Richardson×8
Invite
P. Richardson — researcher profile on SciRah
P. Moreau×7
Invite
P. Moreau — researcher profile on SciRah

×7

Invite

Da Zhang — researcher profile on SciRah

Invite

R. Bannerji — researcher profile on SciRah

Invite

D. Dytfeld — researcher profile on SciRah

J. San-Miguel×6

Invite

J. San-Miguel — researcher profile on SciRah

Invite

J. Laubach — researcher profile on SciRah

P. Statkevich×6

Invite

P. Statkevich — researcher profile on SciRah

Invite

N. Takezako — researcher profile on SciRah

Invite

M. Hori — researcher profile on SciRah